3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
54
Endocrine
54
Gastrointestinal
7
CNS
7
Thoracic
6
Genitourinary
4
Dermatologic
4
Sarcoma
3
Gynecologic
3
Breast
3
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Lymphoid
2
NET
1
Conditions
Leukemia, Myeloid, Acute
885
Precursor Cell Lymphoblastic Leukemia-Lymphoma
511
Hematologic Neoplasms
466
Leukemia, Lymphocytic, Chronic, B-Cell
392
Leukemia
337
Myelodysplastic Syndromes
330
Lymphoma
208
Lymphoma, Non-Hodgkin
191
Multiple Myeloma
146
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
142
Recurrence
138
Neoplasms
135
Leukemia, Myelomonocytic, Chronic
112
Burkitt Lymphoma
93
Lymphoma, Mantle-Cell
92
Lymphoma, Follicular
92
Lymphoma, Large B-Cell, Diffuse
91
Myeloproliferative Disorders
84
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
83
Leukemia, Biphenotypic, Acute
81
Lymphoma, B-Cell, Marginal Zone
75
Hodgkin Disease
72
Lymphoma, B-Cell
64
Waldenstrom Macroglobulinemia
54
Primary Myelofibrosis
54
Leukemia, B-Cell
52
Anemia, Refractory, with Excess of Blasts
46
Leukemia, Myeloid, Chronic-Phase
41
Hematologic Diseases
37
Lymphoma, T-Cell
33
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thyroid Cancer, Papillary
×
Other hematologic neoplasm
×
1 year
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled